Primeri bilinmeyen kanserde F(18)-FDG PET/BT tetkikinin tanıya katkısı
Amaç: Bu çalışmanın amacı, primeri bilinmeyen kanser (PBK) hastalarında 18F-florodeoksiglukoz pozitron emisyon tomografisi/bilgisayarlı tomografinin (F18-FDG PET/BT) klinik olarak tanıya katkısını değerlendirmektir. Yöntem: Retrospektif, kesitsel analiz çalışmasında Haziran 2014-Temmuz 2015 tarihleri arasında 124 PBK hastalarının F18-FDG PET/BT incelemesi yapıldı. Artmış 18F-FDG tutulum odağının histopatoloji ile korelasyonu değerlendirildi. F18-FDG PET/BT için tanısal doğruluk, duyarlılık, özgüllük, pozitif öngörü değeri ve negatif öngörü değerleri hesaplandı. Bulgular: F18-FDG PET/BT, yüksek F18-FDG tutulumu olan 56 hastada primer tümör odağını başarıyla saptadı (gerçek pozitif, % 45.2). 58 hastada histopatolojik ve klinik olarak primer tümör bulunamadı (gerçek negatif, % 46.8). 8 hastada yüksek F18-FDG uptake tutulumu olmasına karşın histopatolojik ve klinik olarak primer tümör kanıtı yoktu (yanlış pozitif, % 6.4). Sadece 2 hastada negatif F18-FDG PET/BT tarama sonuç bulunmasına karşın primer tümör histopatolojik olarak saptandı (yanlış negatif, % 1.6) primer yerleşim lokalizasyonu için negatif idi. Genel olarak tanısal doğruluk % 91.9, duyarlılık % 96.5, özgüllük % 87.8, pozitif öngörü değeri % 87.5, negatif öngörü değeri % 96.6, pozitif olabilirlik oranı % 7.9 ve negatif olabilirlik oranı % 0.04 olarak bulundu. Sonuç: PBK hastalarının tanısında F18-FDG PET/BT’nin yararlı olabileceği düşünülebilir.
The diagnostic contribution of (18)F-FDG PET/CT scan in cancer of unknown primary
Objective: The aim of the present study was to evaluate the clinically diagnostic contribution of 18Ffluorodeoxyglucosepositron emission tomography combined with computed tomography (18F-FDG PET/CT) inpatients with cancer of unknown primary (CUP).Method: The retrospective investigation, cross-sectional analysis of 124 18F-FDG PET/CT scans of patients with CUPbetween June 2014 and July 2015 was performed. The increased 18F-FDG uptake focus were assessed in correlationwith histopathology. The diagnostic accuracy, sensitivity, specificity, positive predictive value and negative predictivevalues were assessed for 18F-FDG PET/CT.Results: The 18F-FDG PET/CT successfully detected primary tumor in 56 patients with high 18F-FDG uptakeinvolvement (true positive, 45.2%). 58 patients whose final histopathology and clinically without evidence of a primarytumor (true negative, 46.8%). 8 patients whose final histopathologicallyand clinically without evidence of a primarytumor but high 18F-FDG uptake involvement (false positive, 6.4%). The 18F-FDG PET/CT scan results were negativefor primary site localization in only 2 patients with no 18F-FDG uptake involvement (false negative, 1.6%). Generally,the diagnostic accuracy was found to be 91.9%, sensitivity 96.5%, specificity 87.8%, positive predictive value 87.5%,negative predictive value 96.6%, positive likelihood ratio 7.9% and negative likelihood ratio 0.04%.Conclusions: It can be said that 18F-FDG PET/CT may be useful in the diagnosis of patients with CUP.
___
- Fizazi K, Greco FA, Pavlidis N. Cancers
of unknown primary site: ESMO Clinical
Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol
2011;22 Suppl 6:vi64-68.
- Elboga U, Kervancioğlu S, Sahin E,
Basibuyuk M, Celen YZ, Aktolun C.
Utility of F-18 fluorodeoxyglucose
posıtron emıssıon tomography/computed
ın carcınoma of unknown primary. Int J
Clin Exp Pathol 2014;7(12):8941-6.
- Pavlidis N, Fizazi K. Carcinoma of
unknown primary (CUP). Crit Rev Oncol
Hematol 2009;69:271-8.
- Klein CA. Parallel progression of primary
tumors and metastases. Nat Rev Cancer
2009;9:302-12.
- Kwee TC, Basu S, Alavi A. PET and
PET/CT for unknown primary tumors.
Methods Mol Biol 2011;727:317-33.
- Hasbek Z, Doğan ÖT, Sarı İ, Yücel B,
Şeker MM, Turgut B, Berk S, Siliğ Y.
The Diagnostic Value of the Correlation
between Serum Anti-p53 Antibody and
Positron Emission Tomography
Parameters in Lung Cancer. Mol Imaging
Radionucl Ther 2016;25(3):107-13.
- Kwee TC, Kwee RM. Combined FDGPET/
CT for the detection of unknown
primary tumors: systematic review and
meta-analysis. Eur Radiol
2009;19(3):731-44.
- Bochtler T, Löffler H, Kramer A.
Diagnosis and management of metastatic
neoplasms with unknown primary. Semin
Diagn Pathol 2017. pii: S0740-
2570(17)30147-8.
- Riaz S, Nawaz MK, Faruqui ZS, Kazmi
SA, Loya A, Bashir H. Diagnostic
Accuracy of 18F-Fluorodeoxyglucose
Positron Emission Tomography-
Computed Tomography in the Evaluation
of Carcinoma of Unknown Primary. Mol
Imaging Radionucl Ther 2016;25(1):11-8.
- Talavera-Rubio MP, Garcia-Vicente AM,
Palomar-Munoz AM, Pilkington-Woll JP,
Poblete-Garcia VM, Soriano-Castrejon A.
Usefulness of (18) F-fluorodeoxyglucosepositron
emission tomography
computerized tomography in the
identification of the primary tumor in
patients with cancer of unknown origin.
Med Clin (Barc) 2013;140:14-9.
- Burglin SA, Hess S, Hoilund-Carlsen PF,
Gerke O. 18F-FDG PET/CT for detection
of the primary tumor in adults with
extracervical metastases from cancer of
unknown primary: A systematic review
and meta-analysis. Medicine (Baltimore)
2017;96(16):e6713.
- Börksüz MF, Erselcan T, Hasbek Z,
Yücel B, Turgut B. Morphologic and
Metabolic Comparison of Treatment
Responsiveness with 18Fludeoxyglucose-
Positron Emission
Tomography/Computed Tomography
According to Lung Cancer Type. Mol
Imaging Radionucl Ther 2016;25(2):63-9.
- Hasbek Z, Yucel B, Salk I, Turgut B,
Erselcan T, Babacan NA, Kacan T.
Potential impact of atelectasis and
primary tumor glycolysis on F-18 FDG
PET/CT on survival in lung cancer
patients. Asian Pac J Cancer Prev
2014;15(9):4085-9.
- Santhanam P, Chandramahanti S, Kroiss
A, Yu R, Ruszniewski P, Kumar R, et al.
Nuclear imaging of neuroendocrine
tumors with unknown primary: why,
when and how? Eur J Nucl Med Mol
Imaging 2015;42(7):1144-55.
- Özman Ö, Arslan N. The Role of PET/CT
in Head and Neck Cancer. Turkiye
Klinikleri J E.N.T.-Special Topics
2010;3(4):72-81.
- Su YY, Chen SS, Hsieh CH, Liao CT, Lin
CY, Kang CJ, et al. Defining risk groups
of patients with cancer of unknown
primary site and cervical nodal metastases by F-18 fluorodeoxyglucose positron
emission tomography and computed
tomography imaging. Kaohsiung J Med
Sci 2016;32(8):407-13.
- İnan İE, Kılıç C, Tunçel Ü. The
correlation of positron emission
tomography-computed tomography
assessment with histopathological results
in the diagnosis of head and neck cancer
of unknown primary. Kulak Burun Bogaz
Ihtis Derg 2012;22(6):319-23.
- Roh JL, Kim JS, Lee JH, Cho KJ, Choi
SH, Nam SY, et al. Utility of combined
(18)F-fluorodeoxyglucose-positron
emission tomography and computed
tomography in patients with cervical
metastases from unknown primary
tumors. Oral Oncol 2009;45:218-24.
- Nassenstein K, Veit-Haibach P, Stergar
H, Gutzeit A, Freudenberg L, Kuehl H, et
al. Cervical lymph node metastases of
unknown origin: primary tumor detection
with whole-body positron emission
tomography/computed tomography. Acta
Radiol 2007;48:1101-8.
- Wang G, Wu Y, Zhang W, Li J, Wu P,
Xie C. Clinical value of whole-body F-18
fluorodeoxyglucose positron emission
tomography/computed tomography in
patients with carcinoma of unknown
primary. J Med Imaging Radiat Oncol
2013;57:65-71.
- Algin E, Ozet A, Gumusay O, Cetin B,
Akdemir UO, Benekli M, et al.
Association between survival and
maximum standardized uptake value of
liver metastases detected by 18-fluoro-2-
deoxy-D-glucose positron emission
tomography-computed tomography in
patients with adenocarcinoma of unknown
primary origin. Ann Nucl Med
2014;28(9):891-6.
- Ouyang L, Shi ZY, Lin ZG. 18F-FDG
PET-CT makes a significant contribution
to diagnosis of malignancy in patients
with cervical lymphadenopathy: a study
using optimal scale regression tests. Chin
Med J (Engl) 2013;126:659-67.
- Chorost MI, Lee MC, Yeoh CB, Molina
M, Ghosh BC. Unknown primary. J Surg
Oncol 2004;87(4):191-203.
- Regelink G, Brouwer J, de Bree R.
Detection of unknown primary tumours
and distant metastases in patients with
cervical metastases: value of FDG-PET
versus conventional modalities. Eur J
Nucl Med Mol Imaging 2002;29(8):1024-
30.
- Stokkel MP, Bongers V, Hordijk GJ, van
Rijk PP. FDG positron emission
tomography in head and neck cancer:
pitfall or pathology? Clin Nucl Med.
1999;24:950-4.
- Çakır T, Atasever T. F-18 Flourodeoxy
Glucose Positron Emission Tomography/
Computed Tomography Imaging in
Infection and Inflammation. Nucl Med
Semin 2016;2:79-89.
- Nassenstein K, Veit-Haibach P, Stergar
H, Gutzeit A, Freudenberg L, Kuehl H, et
al. Cervical lymph node metastases of
unknown origin: primary tumor detection
with whole-body positron emission
tomography/computed tomography. Acta
Radiol 2007;48:1101-8.
- Gutzeit A, Antoch G, Kühl H, Egelhof T,
Fischer M, Hauth E, et al. Unknown
primary tumors: detection with dualmodality
PET/CT-initial experience.
Radiology 2005;234:227-34.
- Kaya AO, Coskun U, Unlu M, Akdemir
UO, Ozdemir NY, Zengin N, et al. Whole
body 18F-FDG PET/CT imaging in the
detection of primary tumours in patients
with a metastatic carcinoma of unknown
origin. Asian Pac J Cancer Prev
2008;9:683-6.
- Kole AC, Nieweg OE, Pruim J. Detection
of unknown occult primary tumors using
positron emission tomography. Cancer
1998;82:1160-6.